Search results for "Endometrial cancer"

showing 10 items of 94 documents

Expression Profile of VEGF-C, VEGF-D, and VEGFR-3 in Different Grades of Endometrial Cancer

2019

Background:Vascular endothelial growth factor (VEGF)-C, -D, and VEGF receptor-3 are proteins characterized as crucial for tumor lymphangiogenesis. It is accompanied by angiogenesis during wound healing, but also in the neoplastic process. The research studies have shown that the lymphatic system plays a key role in the progression of carcinogenesis.Objective:The aim of this study was to evaluate changes in the expression of VEGF-C, VEGF-D and VEGFR-3 in different grades of endometrial cancer (G1-G3).Methods:The study included 45 patients diagnosed with endometrial cancer (G1=17; G2=15; G3=13) and 15 patients without neoplastic changes. The expression of VEGF-C, VEGF-D, and VEGFR-3 was asses…

0301 basic medicineAngiogenesisVascular Endothelial Growth Factor CVascular Endothelial Growth Factor DVEGF-CPharmaceutical ScienceVEGF-Dmedicine.disease_causeMetastasisTranscriptome03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansANOVANeovascularization Pathologicbusiness.industryEndometrial cancerCancerVascular Endothelial Growth Factor Receptor-3medicine.diseaseImmunohistochemistryEndometrial NeoplasmsLymphangiogenesisVEGFR-3lymphangiogenesisVascular endothelial growth factor030104 developmental biologychemistry030220 oncology & carcinogenesisendometrial cancerCancer researchFemaleNeoplasm GradingCarcinogenesisbusinessBiotechnologyCurrent Pharmaceutical Biotechnology
researchProduct

Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants:a Prospective Lynch Syndrome Database r…

2021

Purpose: This study aimed to report the uptake of hysterectomy and/or bilateral salpingo-oophorectomy (BSO) to prevent gynaecological cancers (risk-reducing surgery [RRS]) in carriers of pathogenic MMR (path_MMR) variants.Methods: The Prospective Lynch Syndrome Database (PLSD) was used to investigate RRS by a cross-sectional study in 2292 female path_MMR carriers aged 30-69 years.Results: Overall, 144, 79, and 517 carriers underwent risk-reducing hysterectomy, BSO, or both combined, respectively. Two-thirds of procedures before 50 years of age were combined hysterectomy and BSO, and 81% of all procedures included BSO. Risk-reducing hysterectomy was performed before age 50 years in 28%, 25%,…

0301 basic medicineCancer ResearchOophorectomyDatabases FactualColorectal cancerSURGERYmedicine.medical_treatmentCàncer d'ovaricomputer.software_genreDNA Mismatch Repair0302 clinical medicineEndometrial cancermunasarjasyöpäMedicineProspective StudiesColectomySalpingo-oophorectomy/methodsDatabaseManchester Cancer Research CentreCOLON-CANCERMLH1WOMENMiddle AgedPrognosisLynch syndrome3. Good healthkohdunrungon syöpäOncologyCOLECTOMY030220 oncology & carcinogenesisFemaleBiomarkers Tumor/geneticsAdultHeterozygoteGenital Neoplasms FemaleSalpingo-oophorectomyHysterectomy03 medical and health sciencesGenital Neoplasms Female/prevention & controlOvarian cancerColorectal Neoplasms Hereditary Nonpolyposis/geneticsBiomarkers TumorMortalitatHumansHysterectomy/methodsMortalityLynchin oireyhtymäRisk-reducing surgeryAgedHysterectomybusiness.industryEndometrial cancerResearchInstitutes_Networks_Beacons/mcrcCancerOophorectomyMSH63126 Surgery anesthesiology intensive care radiologymedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisMSH2030104 developmental biologyCross-Sectional StudiesLynch syndromePMS2Càncer d'endometriMutationkohdunpoistobusinessOvarian cancercomputerFollow-Up Studies
researchProduct

Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas.

2018

AbstractObjective The diagnosis of carcinoma in both the uterus and the ovary simultaneously is not uncommon and raises the question of synchronous primaries vs. metastatic disease. Targeted sequencing of sporadic synchronous endometrial and ovarian carcinomas has shown that such tumors are clonally related and thus represent metastatic disease from one site to the other. Our purpose was to investigate whether or not the same applies to Lynch syndrome (LS), in which synchronous cancers of the gynecological tract are twice as frequent as in sporadic cases, reflecting inherited defects in DNA mismatch repair (MMR). Methods MMR gene mutation carriers with endometrial or ovarian carcinoma or en…

0301 basic medicineCarcinogenesis3122 CancersEndometrial hyperplasiaGene mutationMismatch repair03 medical and health sciences0302 clinical medicineGermline mutationEndometrial cancerOvarian cancer3123 Gynaecology and paediatricsOvarian carcinomamunasarjasyöpäCarcinomamedicineHumansLynchin oireyhtymäHypermethylationOvarian Neoplasmsbusiness.industryEndometrial cancerObstetrics and Gynecologyta3122medicine.diseaseta3123Colorectal Neoplasms Hereditary NonpolyposisLynch syndrome3. Good healthEndometrial hyperplasiaEndometrial Neoplasmshypermethylationmismatch repairkohdunrungon syöpä030104 developmental biologyLynch syndromeOncology030220 oncology & carcinogenesisCancer researchsyöpätauditFemaleOvarian cancerbusinessendometrial hyperplasiaGynecologic oncology
researchProduct

Abstract CT046: A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors

2018

Abstract Background: PIK3CA, a gene that encodes the α-isoform of the catalytic subunit of Class I PI3K (PI3Kα), is frequently mutated or amplified in solid tumors. Taselisib is an oral, potent, selective inhibitor of Class I PI3Kα, γ, and δ isoforms with enhanced activity against PIK3CA-mutated cancer models. Preclinical and clinical data demonstrated that single-agent taselisib has activity in multiple PIK3CA-mutated tumor types. Methods: This open-label phase I study (Cohort X of PMT4979g; NCT01296555) enrolled patients (pts) with PIK3CA-mutated tumors who had progressed after, or failed to respond to, at least one prior treatment regimen and were not candidates for regimens known to pro…

0301 basic medicineCervical cancerCancer Researchmedicine.medical_specialtybusiness.industryEndometrial cancerNot Otherwise SpecifiedCancermedicine.diseaseGastroenterologyHead and neck squamous-cell carcinoma03 medical and health sciencesRegimen030104 developmental biologyOncologyTolerabilityResponse Evaluation Criteria in Solid TumorsInternal medicinemedicinebusinessCancer Research
researchProduct

Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level

2018

The system integrated by the receptor activator of nuclear factor kappa B (RANK) and its ligand, RANKL, modulates the role of hormones in the genesis and progression of breast tumors. We investigated whether the expression of RANK was related with clinicopathological features of primary endometrial tumors. Immunohistochemistry was used in an endometrial cancer tissue array containing samples from 36 tumors. The amount of RANK mRNA was examined in a tissue scan cDNA array containing cDNA from 40 tumors. Normal endometrium was examined for comparison. Immunohistochemical analyses showed that RANK expression was higher in malignant than in normal endometrium (p &lt

0301 basic medicineEndometriumRANKlcsh:Chemistry0302 clinical medicineGene expressionProtein IsoformsendometriumReceptorlcsh:QH301-705.5SpectroscopyReceptor Activator of Nuclear Factor-kappa BbiologyGeneral MedicineMiddle AgedComputer Science ApplicationsGene Expression Regulation Neoplasticmedicine.anatomical_structureRANKL030220 oncology & carcinogenesisendometrial cancerimmunohistochemistryImmunohistochemistryFemaleAdultGene isoformAdenocarcinomaArticleCatalysisInorganic Chemistry03 medical and health sciencesmedicineHumansRNA MessengerPhysical and Theoretical ChemistryMolecular BiologyNeoplasm StagingActivator (genetics)Endometrial cancerOrganic Chemistrymedicine.diseaseEndometrial NeoplasmsAlternative Splicing030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Tissue Array Analysisgene expressionCancer researchbiology.proteinprognosisNeoplasm GradingInternational Journal of Molecular Sciences
researchProduct

Monitoring of rheologic variables during postoperative high-dose brachytherapy for uterine cancer.

2004

Oxygenation of tumor tissue has recently been assed an important prerequisite for the effectiveness of radiotherapy in cervical cancer. Hyperviscosity is a common phenomenon in malignancy and a cause of reduced oxygen transport capacity that would favour tissue hypoxia. Hemorheological variables were serially tested preoperatively, during four cycles of fractionated adjuvant IR192 HDR after loading radiation (HDR-AL) of the vaginal vault (weekly intervals), and 6 months postoperatively in patients with cervical (n=12) and endometrial cancer (n=26). Women who were scheduled for benign tumor surgery served as controls (n=29). Preoperatively, in cervical and endometrial cancer patients, mean …

0301 basic medicineErythrocyte Aggregationmedicine.medical_specialtymedicine.medical_treatmentBrachytherapyBrachytherapyUrologyUterine Cervical Neoplasms030204 cardiovascular system & hematologyHysterectomy03 medical and health sciencesLeukocyte Count0302 clinical medicineUterine cancermedicineHumansAgedCervical cancerbusiness.industryPlatelet CountEndometrial cancerOxygen transportFibrinogenHematologyGeneral MedicineMiddle Agedmedicine.diseaseBlood ViscosityCombined Modality TherapyCell HypoxiaSurgeryEndometrial NeoplasmsRadiation therapy030104 developmental biologyHemorheologyVaginal vaultFemaleRadiotherapy AdjuvantbusinessBiomarkersClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
researchProduct

ASO Author Reflections: How Long will We Perform Lymphadenectomy in Endometrial Cancer Patients?

2022

Abstract Objectives To compare survival and progression outcomes between 2 nodal assessment approaches in patients with nonbulky stage IIIC endometrial cancer (EC). Methods Patients with stage IIIC EC treated at 2 institutions were retrospectively identified. At 1 institution, a historical series (2004–2008) was treated with systematic pelvic and para-aortic lymphadenectomy (LND cohort). At the other institution, more contemporary patients (2006–2013) were treated using a sentinel lymph node algorithm (SLN cohort). Outcomes (hazard ratios [HRs]) within the first 5 years after surgery were compared between cohorts using Cox models adjusted for type of adjuvant therapy. Results The study incl…

0301 basic medicineN.A.medicine.medical_specialtymedicine.medical_treatmentSentinel lymph nodeMEDLINEArticleEndometrial CancerDisease-Free Survival03 medical and health sciences0302 clinical medicineLymphadenectomy Endometrial CancerSurgical oncologyAdjuvant therapymedicineHumansStage IIICNeoplasm InvasivenessProgression-free survivalLymph nodeAgedNeoplasm StagingRetrospective Studiesbusiness.industryEndometrial cancerGeneral surgeryObstetrics and GynecologyLymphadenectomymedicine.diseaseEndometrial Neoplasms030104 developmental biologymedicine.anatomical_structureTreatment OutcomeSettore MED/40 - GINECOLOGIA E OSTETRICIASentinel nodeOncology030220 oncology & carcinogenesisLymphatic MetastasisDisease ProgressionLymph Node ExcisionFemaleSurgeryLymphadenectomySentinel Lymph NodebusinessAlgorithmChemoradiotherapyAlgorithmsAnnals of Surgical Oncology
researchProduct

Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: Prognostic and clinical implications.

2020

Objectives: The interpretation of lymph-vascular space invasion (LVSI) is usually qualitative, as presence or absence. The aim of this study is to investigate the prognostic role of LVSI in patients affected by endometrial cancer, when evaluated with a semiquantitative analysis. Methods: This retrospective multicentre study enrolled patients who received a histologically confirmed diagnosis of endometrial cancer. The assessment of LVSI was semiquantitative in accordance with the three-tiered scoring system (absent, focal and diffuse). Results: Among 1258 patients with surgical-stage endometrial cancer, LVSI has been found in 32.8% of cases (n = 412), whose 12.7% (n = 160) were focal, and 20…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyScoring systemLymph node metastasis03 medical and health sciences0302 clinical medicineEndometrial cancerRecurrenceRisk FactorsInternal medicinemedicineHumansIn patientLVSIGrading (tumors)business.industryEndometrial cancerNodal metastasisMiddle Agedmedicine.diseaseLymph-vascular space invasionPrognosisSurvival AnalysisEndometrial NeoplasmsVascular space030104 developmental biologySettore MED/40 - GINECOLOGIA E OSTETRICIAOncology030220 oncology & carcinogenesisLymphatic MetastasisFemaleLymphbusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Response: Methods for second primary cancers evaluation have to be standardized

2017

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryIncidence (epidemiology)Endometrial cancerCancerSecond primary cancermedicine.diseaseSecond Primary CancersCancer registry03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineEpidemiology of cancermedicineEtiologybusinessInternational Journal of Cancer
researchProduct

Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer

2019

Background: VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 are important proteins involved in the induction and development of a new blood vessel network through which the tumor is properly nourished and oxygenated. Objective: The aim of the study was to evaluate changes in VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 expression in endometrial cancer depending on its grade and to determine the VEGFR-1 to VEGFR-2 concentration ratio. Methods: The study group consisted of 45 patients diagnosed with endometrial cancer (G1, 17; G2, 15; G3, 13). The control group included 15 patients. VEGF-A, VEGF-B, VEGF-R1, VEGFR-2 expression was assessed using the immunohistochemical method. Statistical analysis was carried out…

0301 basic medicineOncologyTumor angiogenesisVascular Endothelial Growth Factor Amedicine.medical_specialtyVascular Endothelial Growth Factor BVEGF-A/BAngiogenesisPharmaceutical ScienceArticle03 medical and health sciencesangiogenesis0302 clinical medicineInternal medicineMedicineHumansAdenomyosisRNA MessengerVascular Endothelial Growth Factor Receptor-1integumentary systemNeovascularization Pathologicbusiness.industryEndometrial cancerCancerVEGFR-1/2tumor angiogenesismedicine.diseasePrognosisImmunohistochemistryVascular Endothelial Growth Factor Receptor-2Endometrial Neoplasms030104 developmental biologymedicine.anatomical_structureadenomyosis030220 oncology & carcinogenesisCase-Control Studiesembryonic structuresendometrial cancercardiovascular systemImmunohistochemistryFemaleAnalysis of varianceNeoplasm GradingbusinessBiotechnologyBlood vesselCurrent Pharmaceutical Biotechnology
researchProduct